A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

被引：3
|
作者：
Lakhani, Nehal J.
Rasco, Drew W.
Tolcher, Anthony W.
Huang, Yingjie
Ji, Jiao
Wang, Hengbang
Dong, Qi
Men, Lichuang
O'Rourke, Timothy J.
Chandana, Sreenivasa R.
Amaya, Alex
Cole, Yvette
Kaiser, Brianne
Mays, Theresa A.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Yang, Dajun
Zhai, Yifan
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[3] Ascentage Pharma Grp Inc, Rockville, MD USA
[4] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[5] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[6] Canc & Hem Ctr West Michigan, Grand Rapids, MI USA
[7] Western Michigan Canc Ctr, Kalamazoo, MI USA
[8] START Ctr Canc Care, San Antonio, TX USA
[9] START Midwest Canc Hematol Centers Western Michig, Grand Rapids, MI USA
[10] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[11] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2594
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line
    Mohammad, RM
    Wang, SM
    Banerjee, S
    Wu, XH
    Chen, JY
    Sarkar, FH
    PANCREAS, 2005, 31 (04) : 317 - 324
  • [42] A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
    Schimmer, Aaron D.
    O'Brien, Susan
    Kantarjian, Hagop
    Brandwein, Joseph
    Cheson, Bruce D.
    Minden, Mark D.
    Yee, Karen
    Ravandi, Farhad
    Giles, Francis
    Schuh, Andre
    Gupta, Vikas
    Andreeff, Michael
    Koller, Charles
    Chang, Hong
    Kamel-Reid, Suzanne
    Berger, Mark
    Viallet, Jean
    Borthakur, Gautam
    CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8295 - 8301
  • [43] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Chen, Zi
    Huang, Bo
    Konopleva, Marina
    Brander, Danielle M.
    Rizzieri, David
    Lasica, Masa
    Tam, Constantine Si Lun
    Yannakou, Costas K.
    Prince, H. Miles
    Davids, Matthew Steven
    He, Zhicong
    Lu, Ming
    Ahmad, Mohammad
    Li, Mingyu
    Liang, Zhiyan
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chiappori, A.
    Schreeder, M. T.
    Moezi, M. M.
    Stephenson, J.
    Blakely, J. L.
    Salgia, R.
    Chu, Q. S.
    Malik, S. M.
    Modiano, M. M.
    Berger, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
    Marshall, J
    Chen, H
    Yang, D
    Figueira, M
    Bouker, KB
    Ling, Y
    Lippman, M
    Frankel, SR
    Hayes, DF
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1274 - 1283
  • [46] A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
    Li, Jianyong
    Zhou, Keshu
    Nian, Weiqi
    Cui, Guohui
    Wang, Jishi
    Zhang, Xiaoping
    Cen, Hong
    Li, Fei
    Yi, Shuhua
    Feng, Ru
    Xu, Chongyuan
    Qian, Wenbin
    Liu, Lihong
    Li, Caixia
    Zhao, Xielan
    Chen, Zi
    Qiao, Junxiao
    Zhang, Hongli
    Ahmad, Mohammad
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Rudin, CM
    Kozloff, M
    Hoffman, PC
    Edelman, MJ
    Karnauskas, R
    Tomek, R
    Szeto, L
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1110 - 1117
  • [48] Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer
    Shibata, Y
    Hidaka, S
    Tagawa, Y
    Nagayasu, T
    ANTICANCER RESEARCH, 2004, 24 (3B) : 1925 - 1928
  • [49] First-in-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients With Relapsed/Refractory CLL and Other Hematologic Malignancies
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 10 - 11
  • [50] A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
    Paik, Paul K.
    Rudin, Charles M.
    Pietanza, Maria C.
    Brown, Andrew
    Rizvi, Naiyer A.
    Takebe, Naoko
    Travis, William
    James, Leonard
    Ginsberg, Michelle S.
    Juergens, Rosalyn
    Markus, Susan
    Tyson, Leslie
    Subzwari, Sara
    Kris, Mark G.
    Krug, Lee M.
    LUNG CANCER, 2011, 74 (03) : 481 - 485
12345